Ongoing Clinical Trials for Preterm Premature Rupture of Membranes
There are currently 2 clinical trials investigating treatment approaches for preterm premature rupture of membranes. These studies are exploring different strategies to manage this pregnancy complication, including personalized antibiotic and steroid treatments, as well as early labor induction methods. The trials are taking place in Czechia and Italy, aiming to improve outcomes for both mothers and babies.
Clinical trial locations
- Czechia
- Italy
Study on Betamethasone Sodium Phosphate and Drug Combination for Pregnant Women with Preterm Premature Rupture of Membranes
This trial is investigating a personalized treatment approach for women who experience early rupture of the amniotic sac before 37 weeks of pregnancy. The condition, known as preterm premature rupture of membranes, occurs when the protective sac holding the baby and amniotic fluid breaks earlier than expected, which can increase the risk of infection and lead to premature birth.
Main inclusion criteria: Women eligible for this study must be at least 18 years old and between 22 and 33 weeks and 6 days of pregnancy. They must be pregnant with a single baby and have a confirmed diagnosis of preterm premature rupture of membranes, either through a test called Amnisure or by a doctor’s examination. The pregnancy must have been completely uncomplicated before the rupture occurred. Participants must provide written consent to join the study.
Main exclusion criteria: This study is only for pregnant women, so men cannot participate. Women who do not have preterm premature rupture of membranes or who fall outside the specified pregnancy weeks and age range are not eligible. Those who are part of vulnerable populations and cannot give proper consent are also excluded.
Trial focus and approach: The study aims to develop a tailored treatment plan based on the level of a substance called IL-6 in the amniotic fluid. This measurement is obtained through a procedure called amniocentesis, where a small sample of amniotic fluid is collected. Based on these results, doctors will create a personalized treatment plan to safely prolong the pregnancy and improve health outcomes for both mother and baby while reducing unnecessary antibiotic use.
Investigational drugs: The trial uses two main types of treatment. Antibiotic therapy includes gentamicin, benzylpenicillin, demeclocycline hydrochloride, and ampicillin combined with a beta-lactamase inhibitor. These antibiotics help prevent or treat infections that can occur when the protective amniotic sac breaks early. Steroid therapy involves dexamethasone, which helps the baby’s lungs develop more quickly in case of early birth. Since the lungs are one of the last organs to fully mature, this treatment can reduce breathing problems in premature newborns. Additionally, magnesium sulfate is included for its protective effects on the baby’s developing nervous system.
Study of oxytocin, dinoprostone, and misoprostol combination for active management in pregnant women with premature rupture of membranes
This study focuses on full-term pregnant women who experience premature rupture of membranes at 37 weeks or later. The condition means the water breaks before labor begins naturally. The trial compares two approaches: starting labor immediately with medications versus waiting for labor to begin on its own.
Main inclusion criteria: Women must be at least 18 years old and have reached at least 37 weeks of pregnancy, which is considered full-term. They must have tested negative for Group B Streptococcus bacteria in a rectovaginal swab test. Six hours after the water breaks, women should have minimal contractions (0-2 contractions every 10 minutes). The baby must be positioned head-down. Participants must be able to understand the study and provide written informed consent.
Main exclusion criteria: Women cannot participate if they have a history of allergic reactions to the study medications, are carrying multiple babies, or have active vaginal bleeding. Other exclusions include infections of the membranes surrounding the baby, known fetal abnormalities affecting breathing, previous uterine surgery including cesarean section, placental complications, active genital herpes infection, or severe medical conditions that could affect pregnancy outcome. Women with preeclampsia, known fetal distress, those planning to relocate during the study, or those who participated in other clinical trials within the past 30 days are also excluded.
Trial focus and approach: The main goal is to determine whether early induction of labor can reduce the need for breathing support in newborns compared to waiting for labor to start naturally. The study tracks how many newborns need breathing assistance after birth and monitors for signs of infection in both mothers and babies. Healthcare providers will also monitor the pattern of uterine contractions and record how long mothers and babies need to stay in the hospital.
Investigational approach: This trial compares two management strategies rather than testing specific new medications. Women assigned to active management will receive medications to help start labor right away, which may include oxytocin (given through a vein to help the uterus contract), dinoprostone (used vaginally to prepare the cervix and induce labor), and misoprostol (taken by mouth to help induce labor). Mifepristone may also be used to help prepare the body for labor. Women in the expectant management group will be monitored while waiting for labor to begin naturally.
Summary
The two clinical trials for preterm premature rupture of membranes represent different approaches to managing this pregnancy complication. The trial in Czechia focuses on earlier gestational ages (22 to 33 weeks) and uses a personalized medicine approach based on inflammation markers to determine antibiotic and steroid treatment. In contrast, the Italian trial addresses full-term pregnancies (37 weeks or later) and compares the timing of labor induction rather than testing new medications.
Both studies aim to improve outcomes for mothers and babies, though they address different stages of pregnancy and use different strategies. The Czech study emphasizes infection prevention and lung development in premature babies, while the Italian study focuses on reducing the need for newborn breathing support at full term. These trials reflect the complexity of managing membrane rupture at different stages of pregnancy and the need for tailored treatment approaches based on gestational age and individual circumstances.
